Abstract
Antithrombin III (ATIII) is an important endogenous anticoagulant protein which functions at the level of serine protease inhibition. ATIII inactivates thrombin, factor Xa and other enzymes in the intrinsic coagulation pathway, thereby decreasing fibrin formation. Inhibition occurs when stable, stoichiometric ATIII-enzyme complexes form as a result of interactions between the reactive site of ATIII and the active site of the protease target.1 The rate of complex formation increases substantially in the presence of heparan sulfate proteoglycans on the surface of the vascular endothelium in vivo,2 or after addition of heparin in vitro or pharmaceutically.1
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Rosenberg RD, Damus PS: The purification and mechanism of action of antithrombin-heparin cofactor. J. Biol. Chem. 248: 6490–6505, 1973
Marcum JA, Rosenberg RD: Anticoagulantly active heparan sulfate proteoglycan and the vascular endothelium. Seminars in Thrombosis and Haemostasis 13: 464–474, 1987
Petersen TE, Dudek-Wojciechowska G, Sottruup-Jensen L, Magnusson S: Primary structure of antithrombin-III (heparin cofactor). Partial homology between alantitrypsin and antithrombin-III, in Collen D, Wiman B, Verstraete M (eds): The physiological inhibitors of coagulation and fibrinolysis. Elsevier-North Holland Biomedical Press, Amsterdam, 1979, pp. 43–54
Bock SC, Wion K, Vehar G, Lawn RM: Cloning and expression of the endogenous anticoagulant protein, human antithrombin III. Nucl. Acids. Res. 10: 8113–8125, 1982
Chandra T, Stackhouse R, Kidd VJ, Woo SLC: Isolation and sequence characterization of a cDNA clone of human antithrombin III. Proc. Natl. Acad. Sci., USA 80: 1845–1848, 1983
Franzen LE, Svensson S, Larm O: Structural studies on the carbohydrate portion of human antithrombin III. J. Biol. Chem. 255: 5090, 1980
Mizuochi T, Fujii J, Kurachi K, Kobata A: Structural studies of the carbohydrate moiety of human antithrombin III. Arch. Biochem. Biophys. 203: 458, 1980
Collen D, Schetz J, DeCock F, Holmer E, Verstraete M: Metabolism of antithrombin III (heparin cofactor) in man: effects of venous thrombosis of heparin administration. Eur. J. Clin. Invest. 7: 27–35, 1977
Conard J, Brosstad F, Larsen ML, Samama M, Abildgaard U: Molar antithrombin concentration in normal human plasma. Haemostasis 13: 363–368, 1983
Thaler E, Lechner K: Antithrombin III deficiency and thromboembolism. Clin. in Haematol. 10: 369–390, 1981
Pizzo SV: Serpin receptor 1: a hepatic receptor that mediates the clearance of antithrombin III-proteinase complexes. Am. J. Med. 87: 10–14, 1989
Carrell RW, Pemberton PA, Boswell DR: The serpins: evolution and adaptation in a family of protease inhibitors. Cold Spring Harbor Symp. Quant. Biol. LII: 527–535, 1987
Sugiyama N, Sasaki T, Iwamoto M, Abiko Y: Binding site of a2-plasmin inhibitor to plasminogen. Biochim. Biophys. Acta 952: 1–7, 1988
Hortin GL, Trimpe BL, Fok KF: Plasmin’s peptide binding specificity: characterization of ligand sites in a2 — antiplasmin. Thromb. Res. 54: 621–632, 1989
Owen WG: Evidence for the formation of an ester between thrombin and heparin cofactor. Biochim. Biophys. Acta 405: 380–387, 1975
Fish WW, Bjork I: Release of a two-chain form of antithrombin from the antithrombin-thrombin complex. Eur. J. Biochem 101: 31–38, 1979
Jornvall H, Fish WW, Bjork I: The thrombin cleavage site in bovine antithrombin. FEBS Lett. 106: 358–362, 1979
Loebermann H, Tokuoka R, Deisenhofer J, Huber R: Human al-proteinase inhbitor. Crystal structure analysis of two crystal modifications, molecular model and preliminary analysis of the implications for function. J. Mol. Biol. 177: 531–556, 1984
Huber R, Carrell RW: Implications of the three-dimensional structure of al-antitrypsin for structure and function of serpins. Biochem. 28: 8951–8966, 1989
Samama JP, Delarue M, Mourey L, Choay J, Moras D: Crystallization and preliminary crystallographic data for bovine antithrombin III. J. Mol. Biol. 210: 877–879, 1989
Brennan SO, Borg JY, George PM, Soria C, Soria J, Caen J, Carrell RW: New carbohydrate site in mutant antithrombin (7-ile > asn) with decreased heparin affinity. FEBS Lett. 237: 118–122, 1988
Borg JY, Brennan SO, Carrell RW, George P, Perry DJ, Shaw J: Antithrombin Rouen-IV 24 Arg > Cys. The amino terminal contribution to heparin binding. FEBS Lett. 266: 163–166, 1990
Chang JY, Tran TH: Antithrombin III Basel: Identification of a pro-leu substitution in a hereditary abnormal antithrombin with impaired heparin cofactor activity. J. Biol. Chem. 261: 1174–1176, 1986
Molho-Sabatier P, Aiach M, Gaillard I, Fiessinger JN, Fischer AM, Chadeuf G, Clauser E: Molecular characterization of seven ATIII variants using PCR. Identification of a new mutation: 384 Ala-Pro. J. Clin. Invest. 83: 1236–1242, 1989
Daly M, Ball R, O’Meara A, Hallinan FM: Identification and characterisation of an antithrombin III mutant (AT Dublin 2) with marginally decreased heparin activity. Thromb. Res. 56: 503–513, 1989
Koide T, Odani S, Takahashi K, Ono T, Salmagawa N: Antithrombin III Toyama: replacement of arginine-47 by cysteine in hereditary abnormal antithrombin III that lacks heparin binding ability. Proc. Natl. Acad. Sci., USA 81: 289, 1984
Duchange N, Chasse JF, Cohen GN, Zakin MM: Molecular characterization of the antithrombin III Tours deficiency. Thromb. Res. 45: 115–121, 1987
Brunei F, Duchange N, Fischer AM, Cohen GN, Zakin MM: Antithrombin III Alger: an new case of arg47> cys mutation. A. J. Hemat. 25: 223–224, 1987
Owen MC, Shaw GJ, Grau E, Foncuberta J, Carrell RW, Boswell DR: Molecular characterization of antithrombin Barcelona-2: 47 arginine to cysteine. Thromb. Res. 55: 451–457, 1989
Owen MC, Borg JY, Soria C, Soria J, Caen J, Carrell RW: Heparin binding defect in a new antithrombin III variant: Rouen, 47 arg to his. Blood 69: 1275–1279, 1987
Caso R, Lane DA, Thomson E, Zangouras D, Panico M, Morris H, Olds RJ, Thein SL, Girolami A: Antithrombin Padua I: Impaired heparin binding caused by an arg-47 to his (CGT to CAT) substitution. Thromb. Res. 58: 185–190, 1990
Borg JY, Owen MC, Soria C, Soria J, Caen J, Carrell RW: Proposed heparin binding site in antithrombin based on arginine 47: a new variant Rouen-II, 47 arg to ser. J. Clin. Invest. 1292–1296, 1988
Devraj-Kizuk R, Chui DHK, Prochownik EV, Carter CJ, Ofosu FA, Blajchman MA: Antithrombin III Hamilton: a gene with a point mutation (guanine to adenine) in codon 382 causing impaired serine protease reactivity. Blood 72: 1518–1523, 1988
Perry DJ, Harper PL, Fairham S, Daly M, Carrell RW: Antithrombin Cambridge, 384 Ala to Pro: a new variant identified using the polymerase chain reaction. FEBS Lett. 254: 174–176, 1989
Erdjument H, Lane DA, Panico M, DiMarzo V, Morris HR: Single amino acid substitutions in the reactive site of antithrombin leading to thrombosis. J. Biol. Chem. 263: 5589–5593, 1988
Owen MC, Beresford CH, Carrell RW: Antithrombin Glasgow, 393 arg to his: a P1 reactive site variant with increased heparin affinity but no thrombin inhibitory activity. FEBS Letts. 231: 317–320, 1988
Lane DA, Erdjument H, Flynn A, DiMarzo V, Panico M, Morris HR, Greaves M, Dolan G, Preston FE: Antithrombin Sheffield: amino acid substitution at the reactive site (arg 393 to his) causing thrombosis. Brit. J. Heamatol. 71: 91–96, 1989
Erdjument H, Lane DA, Panico M, DiMarzo V, Morris HR, Bauer K, Rosenberg RD: Antithrombin Chicago, amino acid substitution of arginine 393 to histidine. Thromb. Res. 54: 613–619, 1989
Erdjument H, Lane DA, Ireland H, DiMarzo V, Panico M, Morris HR, Tripodi A, Mannucci PM: Antithrombin Milano, single amino acid substitution at the reactive site, arg-393 to cys. Thromb. Haemost. 60: 471–475, 1988
Lane DA, Erdument H, Thompson E, Panico M, DiMarzo V, Morris HR, Leone G, DeStefano V, Thein SL: A novel amino acid substitution in the reactive site of a congenital variant antithrombin. Antithrombin Pescara, arg-393 to pro, caused by a CGT to CCT mutation. J. Biol. Chem. 264: 10020–10204, 1989
Stephens AW, Thalley BS, Hirs CHW: Antithrombin III Denver, a reactive site variant. J. Biol. Chem. 262: 1044–1048, 1987
Olds RJ, Lane D, Caso R, Tripodi A, Mannucci PM, Thein SL: Antithrombin III Milano 2: a single base substitution in the thrombin binding domain detected with PCR and direct genomic sequencing. Nucl. Acids Res. 17: 10511, 1989
Bock SC, Silbermann JA, Wikoff W, Abildgaard U, Hultin MB: Identification of a threonine for alanine substitution at residue 404 of antithrombin III Oslo suggests integrity of the 404-407 region is important for maintaining normal plasma inhibitor levels. Thromb. Haemostas. 62: 494A, 1989
Nakagawa M: Antithrombin III deficiency and its molecular analysis. XIIth Congress of ISTH, Kyoto Satellite Symposium, August 27–28, 1989
Bock SC, Marrinan JA, Radziejewska E: Antithrombin III Utah: Proline-407 to leucine mutation in a highly conserved region near the inhibitor reactive site. Biochem. 27: 6171–6178, 1988
Perry DJ, Carrell RW: CpG dinucleotides are “hotspots” for mutation in the antithrombin III gene. Twelve variants identified using the polymerase chain reaction. Mol. Biol. Med. 6: 239–243, 1989
Bird AP: DNA methylation and the frequency of CpG in animal DNA. Nucl. Acids Res. 8: 1499–1504, 1980
Giddings JC: Molecular Genetics and Immunoanalysis in Blood Coagulation. Ellis Horwood Ltd., Chichester, England. 1988
Blackburn MN, Smith RL, Carson J, Sibley CC: The heparin-binding site of antithrombin III: identification of a critical tryptophan in the amino acid sequence. J. Biol. Chem. 259: 939–941, 1984
Carrell RW, Christey PB, Boswell DR: Serpins: Antithrombin and other inhibitors of coagulation and fibrinolysis, Evidence from amino acid sequences, in Verstraete M, Vermylen J, Lijnen HR, Arnout J (eds): Thrombosis and Haemostasis 1987. Leuven University Press, 1987
Brennan SO, George PM, Jordan RE: Physiological variant of antithrombin III lacks carbohydrate side chain at asn 135. FEBS Lett. 219: 431–436, 1987
Peterson CB, Noyes CM, Pecon JM, Church FC, Blackburn MN: Identification of a lysyl residue in antithrombin which is essential for heparin binding. J. Biol. Chem. 262: 8061–8065, 1987
Liu CS, Chang JY: The heparin binding site of human antithrombin III. J. Biol. Chem. 262: 17356–17361, 1987
Chang JY: Binding of heparin to human antithrombin III activates selective chemical modification at lysine 236. Lys-107, lys-125 and lys 136 are situated within the heparin binding site of antithrombin III. J. Biol. Chem. 264: 3111–3115, 1989
Owen MC, Brennan SO, Lewis JH, Carrell RW: Mutation of antitrypsin to antithrombin. al-antitrypsin Pittsburgh (358 met > arg), a fatal bleeding disorder. N. Engl. J. Med. 309: 694–698, 1983
Stephens AW, Siddiqui A, Hirs CHW: Site-directed mutagenesis of the reactive center (serine 394) of antithrombin III. J. Biol. Chem. 263: 15849–15852, 1988
Bock SC, Skriver K, Nielsen E, Thogersen HC, Wiman B, Donaldson VH, Eddy RL, Marrinan J, Radziejewska E, Huber R, Shows TB, Magnusson S: Human C1 inhibitor: primary structure, cDNA cloning and chromosomal localization. Biochem. 25: 4292–4301, 1986
Levy NJ, Ramesh N, Cicardi M, Harrison RA, Davis AE: Type II hereditary angioneurotic edema that may result from a single nucleotide change in the codon for alanine-436 in the C1 inhibitor gene. Proc. Natl. Acad. Sci., USA 87: 265–268, 1990
Holmes WE, Lijnen HR, Nelles L, Kluft C, Nieuwenhuis HK, Rijken DC, Collen D: a2-antiplasmin Enschede: alanine insertion and abolition of plasmin inhibitory activity. Science 238: 209–211, 1987
Bruch M, Weiss V, Engel J: Plasma serine proteinase inhibitors (serpins) exhibit major conformational changes and a large increase in conformational stability upon cleavage at their reactive sites. J. Biol. Chem. 263: 16626–16630, 1988
Gettins P, Hartens JB: Properties of thrombin — and elastase-modified human antithrombin III. Biochem. 27: 3634–3639, 1988
Haris PI, Chapman D, Harrison RA, Smith KF, Perkins SJ: Conformational transition between native and reactive center cleaved forms of al-antitrypsin by Fourier transform infrared spectroscopy and small-angle neutron scattering. Biochem. 29: 1377–1380, 1990
Gettins P: Absence of large-scale conformational change upon limited proteolysis of ovalbumin, the prototypic serpin. J. Biol. Chem. 264: 3781–3785, 1989
Asakura S, Matsuda M, Yoshida N, Terukina S, Kihara H: A monoclonal antibody that triggers deacylation of an intermediate thrombin-antithrombin III complex. J. Biol. Chem. 264: 13736–13739, 1989
Asakura S, Hirata H, Okazaki H, Hashimoto-Gotoh T, Matsuda M: Hydrophobie residues 382-386 of antithrombin III, ala-ala-ala-ser-thr, serve as an epitope for an antibody which facilitates hydrolysis of the inhibitor by thrombin. J. Biol. Chem. 265: 5135–5138, 1990
Bock SC, Harris JF, Schwartz CE, Ward JH, Hershgold EJ, Skolnick MH: Hereditary thrombosis in a Utah kindred is caused by a dysfunctional antithrombin III gene. Am. J. Hum. Genet. 37: 32-14, 1985
Hultin MB, McKay J, Abildgaard U: Antithrombin Oslo: Type Ib classification of the first reported antithrombin-deficient family, with a review of hereditary antithrombin variants. Thromb. Haemost. 59: 468–473, 1988
Hofker MH, Nukiwa T, van Paassen HMB, Nelen M, Frants RR, Klasen EC, Crystal RG: A Pro > Leu substitution in codon 369 in the alpha-1-antitrypsin variant PIM-Heerlen. Am. J. Hum. Genet. 41: A220, 1987
Egeberg O: Inherited antithrombin deficiency causing thrombophilia. Throm. Diath. Haemorrh. 13: 516–530, 1965
Grandille S, Aiach M, Lane DA, Vidaud D, Molho-Sabatier P, Caso R, de Moerloose P, Fiessinger JN, Clauser E: Important role of Arg-129 in heparin binding site of antithrombin III: identification of a novel mutation arg-129 to gin. J. Biol. Chem. In press.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1991 Springer Science+Business Media New York
About this chapter
Cite this chapter
Bock, S.C. (1991). Antithrombin III Genetics, Structure and Function. In: Hoyer, L.W., Drohan, W.N. (eds) Recombinant Technology in Hemostasis and Thrombosis. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-3698-7_3
Download citation
DOI: https://doi.org/10.1007/978-1-4615-3698-7_3
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-6644-7
Online ISBN: 978-1-4615-3698-7
eBook Packages: Springer Book Archive